Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobitolimod dose-optimization study in active ulcerative colitis
2016-004217-26Phase 2Completed
- Sponsor
- InDex Pharmaceuticals
- Start
- Feb 2017
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis comparing Cobitolimod dose arm(s) with Placebo (2 arms). Primary endpoint: Clinical remission at Week 6. Started Feb 2017; status: completed.
02
Drugs
cobitolimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-004217-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004217-26.